Wockhardt jumps 5 per cent as USFDA excludes drug from import alert
In terms of volume 4.66 lakh shares of the company were traded on BSE and over 26 lakh shares changed hands at NSE during the morning trade.
New Delhi: Shares of drug firm Wockhardt on October 4 rose nearly 5 per cent after the US health regulator excluded one of its drugs - Ceftriazone Sodium - from import alert issued earlier against its active pharmaceutical ingredient manufacturing facility at Ankleshwar.
The scrip gained 4.75 per cent to Rs 936.95 on BSE. At NSE, shares of the company went up 4.57 per cent to Rs 937. In terms of volume, 4.66 lakh shares of the company were traded on BSE and over 26 lakh shares changed hands at NSE during the morning trade.
The United States Food and Drug Administration (USFDA) on September 30, 2016 had posted on its website an update on the Import Alert 66-40 "regarding company's API Unit at Ankleshwar" and excluded Ceftriazone Sodium from it, Wockhardt said in a filing to BSE.
"This will enable the company manufacture and sell Ceftriazone API and formulation to the US market," it added.